Blood or CSF test for circulating tumor cells in aggressive meningioma recurrences

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to develop and validate a liquid biopsy approach by detecting circulating tumor cells in blood and/or CSF from adults with previously operated grade 2 or 3 meningiomas that have recurred. Participants undergo blood draws and lumbar punctures to collect samples, alongside standard clinical assessments. The goal is to see if CTCs can be detected and potentially linked to recurrence or prognosis, enabling a non-invasive monitoring option. This early work is focused on feasibility and methodology rather than therapy. No therapeutic intervention beyond sample collection is performed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years of age
* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024
* Tumour expressing SSTR2A on the initial surgical specimen
* Clinical and/or radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)

Exclusion Criteria:

* Other active ongoing cancer
* Contraindications to lumbar puncture:
* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway/risk of trans-tentorial or amygdalar herniation
* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)
* Infection at the puncture site
* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)
* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)
* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)
* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)
* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)
* Failure to obtain written informed consent

Where it's running

• CHU de Montpellier
  Montpellier, France, France Recruiting

Study contacts

• Study coordinator: Julien BOETTO, Dr
• Email: j-boetto@chu-montpellier.fr
• Phone: 0467337488

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy with IN10018 and dalpiciclib for progressive meningioma

  This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality and 1 other locations · NCT07652762

• JZP3507 (ONC206) for recurrent Grade 2/3 meningioma

  A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · San Francisco, California and 7 other locations · NCT07533942

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.